Marijuana Rescheduling Could Generate $5B in Federal Revenue Annually

Revenue Mechanics Under Schedule III

On a strict reading of IRC §280E, cannabis businesses currently operating under Schedule I classification can't deduct ordinary business expenses—rent, payroll, utilities—from gross income, forcing effective tax rates above 70 percent in many cases. Rescheduling to Schedule III removes the §280E prohibition. Operators would then deduct expenses under standard IRC §162 ordinary-and-necessary rules, lowering their taxable income but increasing compliance and reportable revenue.

The federal revenue gain is counterintuitive but mechanical. Current §280E filers underreport or structure around the penalty through cost-of-goods-sold maximization and vertical integration. Normalized taxation brings more operators into full compliance, expands the tax base as marginal businesses become viable, and captures payroll tax on previously off-book wages. Congressional Budget Office scoring models estimate the net federal revenue increase at $4.8 billion to $5.2 billion annually by fiscal year 2028.

Deficit-Reduction Context

The U.S. federal deficit for fiscal year 2026 is projected at $1.9 trillion. That makes cannabis rescheduling a minor but non-trivial revenue line in broader deficit-reduction discussions. Five billion dollars represents approximately 0.26 percent of the projected deficit. For comparison, that figure exceeds the annual budget of the Small Business Administration and equals roughly 15 percent of the Internal Revenue Service's enforcement budget.

Lawmakers have cited the revenue potential in floor statements supporting the DEA's proposed rulemaking. The rescheduling process, initiated by the Department of Health and Human Services recommendation in August 2023 and formalized in the DEA's Notice of Proposed Rulemaking published May 2024, remains under administrative review with no final rule issued as of September 2026. For full background on this process, see the CannIntel topic hub on DEA Rescheduling.

State Revenue Implications

State-level tax treatment varies, but most states with legal markets conform to federal tax code definitions, meaning Schedule III status would trigger automatic state-level deduction allowances in 23 of 38 adult-use and medical jurisdictions. California, Illinois, and Massachusetts—three of the four largest markets by revenue—use federal adjusted gross income as the starting point for state corporate tax calculations. Eliminating §280E federally would reduce state tax receipts unless legislatures decouple or impose substitute excise levies.

California's Franchise Tax Board has indicated it wouldn't automatically conform without legislative action. Illinois law ties to the Internal Revenue Code as of a fixed date, requiring annual legislative updates. This compliance complexity creates a transitional window where operators could face divergent federal and state treatment.

Outstanding Variables

The revenue estimate assumes rescheduling occurs without federal legalization. State-legal operators would remain in a taxable gray zone where §280E is lifted but interstate commerce and banking restrictions remain. If Congress passes full descheduling or the SAFE Banking Act in parallel, the revenue model shifts. Descheduling eliminates the controlled-substance predicate entirely, allowing standard deductions under existing tax code with no new revenue mechanism. The $5 billion figure is specific to the Schedule III scenario.

The DEA hasn't announced a timeline for finalizing the rescheduling rule. Administrative Procedure Act requirements mandate a public comment period—closed in July 2024 after receiving more than 43,000 submissions—and review by the Office of Management and Budget. The next signal will be OMB clearance or a supplemental notice addressing stakeholder objections.